{"id":63016,"date":"2026-04-13T20:19:39","date_gmt":"2026-04-13T12:19:39","guid":{"rendered":"https:\/\/flcube.com\/?p=63016"},"modified":"2026-04-13T20:19:40","modified_gmt":"2026-04-13T12:19:40","slug":"zhejiang-medicine-plans-hkex-spin-off-of-novocodex-biopharmaceuticals-to-unlock-adc-pipeline-value","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63016","title":{"rendered":"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value"},"content":{"rendered":"\n<p><strong>Zhejiang Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600216:SHA\">SHA: 600216<\/a>) has announced its strategic intention to spin off its innovative biologics subsidiary, <strong>NovoCodex Biopharmaceuticals Ltd.<\/strong>, and list it on the <strong>Hong Kong Stock Exchange (HKEX)<\/strong>. The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage <strong>antibody-drug conjugate (ADC)<\/strong> pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corporate-structure-amp-rationale\">Corporate Structure &amp; Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Entity<\/th><th>Core Business Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Zhejiang Medicine (Parent)<\/strong><\/td><td>Nutritional products (human &amp; animal health), traditional pharmaceuticals, pharmaceutical trading<\/td><\/tr><tr><td><strong>NovoCodex (Subsidiary)<\/strong><\/td><td>Discovery, development, manufacturing, and commercialization of <strong>innovative biologics<\/strong> in oncology and endocrinology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novocodex-pipeline-highlights\">NovoCodex Pipeline Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> Utilizes proprietary <strong>unnatural amino acid site-specific conjugation technology<\/strong> for developing next-generation ADCs with enhanced homogeneity, stability, and therapeutic index.<\/li>\n\n\n\n<li><strong>Lead Assets:<\/strong><\/li>\n\n\n\n<li><strong>ARX788<\/strong>: An ADC in clinical development for oncology indications.<\/li>\n\n\n\n<li><strong>ARX305<\/strong>: Another clinical-stage ADC targeting major disease areas.<\/li>\n\n\n\n<li><strong>Strategic Focus:<\/strong> Concentrated on high-value, complex biologic therapeutics, representing a clear strategic divergence from the parent company\u2019s established operations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Value Unlocks:<\/strong> The spin-off will provide NovoCodex with independent access to capital markets, allowing it to fund its ambitious R&amp;D agenda without diluting Zhejiang Medicine\u2019s shareholders or diverting resources from its core, cash-generative businesses.<\/li>\n\n\n\n<li><strong>Investor Clarity:<\/strong> Separating the high-growth, high-risk biotech asset from the stable, mature parent company offers investors a clearer choice and more precise valuation for each entity\u2019s distinct risk-reward profile.<\/li>\n\n\n\n<li><strong>HKEX as Launchpad:<\/strong> Listing in Hong Kong positions NovoCodex to attract international biotech investors and provides a platform for future global expansion, leveraging HKEX\u2019s strong reputation for hosting innovative life science companies.<\/li>\n\n\n\n<li><strong>Management Focus:<\/strong> The transaction will allow both management teams to focus exclusively on their respective strategic priorities and operational execution.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese Biotech Maturation:<\/strong> This move reflects a growing trend among established Chinese healthcare conglomerates to spin out their innovative R&amp;D arms to capture higher valuations in dedicated biotech markets.<\/li>\n\n\n\n<li><strong>ADC Market Frenzy:<\/strong> With the global ADC market experiencing explosive growth and deal activity, NovoCodex\u2019s proprietary conjugation technology and clinical assets are well-positioned to attract significant investor interest.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> The plan is subject to regulatory approvals, market conditions, and final board and shareholder consent. A formal listing application timeline has not yet been disclosed.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief is based on a corporate announcement of intent. The proposed spin-off and listing are subject to numerous conditions, including but not limited to regulatory approvals, market conditions, and final agreements. There can be no assurance that the transaction will be completed as described or at all.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600216_20260411_FCXN.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600216_20260411_FCXN.\"><\/object><a id=\"wp-block-file--media-3b6321ba-2232-4782-a96a-71d304ce4b19\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600216_20260411_FCXN.pdf\">600216_20260411_FCXN<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600216_20260411_FCXN.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3b6321ba-2232-4782-a96a-71d304ce4b19\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,72,3760,1706,1705],"class_list":["post-63016","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-ipo","tag-novocodex-biopharmaceuticals","tag-sha-600216","tag-zhejiang-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its innovative biologics subsidiary, NovoCodex Biopharmaceuticals Ltd., and list it on the Hong Kong Stock Exchange (HKEX). The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage antibody-drug conjugate (ADC) pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63016\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its innovative biologics subsidiary, NovoCodex Biopharmaceuticals Ltd., and list it on the Hong Kong Stock Exchange (HKEX). The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage antibody-drug conjugate (ADC) pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63016\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:19:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:19:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63016#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63016\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value\",\"datePublished\":\"2026-04-13T12:19:39+00:00\",\"dateModified\":\"2026-04-13T12:19:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63016\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"IPO\",\"NovoCodex Biopharmaceuticals\",\"SHA: 600216\",\"Zhejiang Medicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63016#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63016\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63016\",\"name\":\"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T12:19:39+00:00\",\"dateModified\":\"2026-04-13T12:19:40+00:00\",\"description\":\"Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its innovative biologics subsidiary, NovoCodex Biopharmaceuticals Ltd., and list it on the Hong Kong Stock Exchange (HKEX). The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage antibody-drug conjugate (ADC) pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63016#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63016\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63016#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its innovative biologics subsidiary, NovoCodex Biopharmaceuticals Ltd., and list it on the Hong Kong Stock Exchange (HKEX). The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage antibody-drug conjugate (ADC) pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63016","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value","og_description":"Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its innovative biologics subsidiary, NovoCodex Biopharmaceuticals Ltd., and list it on the Hong Kong Stock Exchange (HKEX). The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage antibody-drug conjugate (ADC) pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.","og_url":"https:\/\/flcube.com\/?p=63016","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:19:39+00:00","article_modified_time":"2026-04-13T12:19:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63016#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63016"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value","datePublished":"2026-04-13T12:19:39+00:00","dateModified":"2026-04-13T12:19:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63016"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","IPO","NovoCodex Biopharmaceuticals","SHA: 600216","Zhejiang Medicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63016#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63016","url":"https:\/\/flcube.com\/?p=63016","name":"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T12:19:39+00:00","dateModified":"2026-04-13T12:19:40+00:00","description":"Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its innovative biologics subsidiary, NovoCodex Biopharmaceuticals Ltd., and list it on the Hong Kong Stock Exchange (HKEX). The move aims to unlock the significant value of NovoCodex\u2019s clinical-stage antibody-drug conjugate (ADC) pipeline, which is distinct from Zhejiang Medicine\u2019s core businesses in nutritional products and traditional pharmaceuticals.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63016#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63016"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63016#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63016"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63016\/revisions"}],"predecessor-version":[{"id":63020,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63016\/revisions\/63020"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}